IGHE and asthma: Before and after 16 weeks of omalizumab treatment, OCS dosage, total serum IgE, EOS count and percentage, FEV1, and the number of acute exacerbations decreased, and the ACT score improved, all with statistically significant differences (p < 0.05), suggesting that the overall efficacy of omalizumab was good, reflecting a reduced OCS dosage, decreased number of acute exacerbations, and improved asthma control after treatment (Table 3).